NCT01276522View on ClinicalTrials.gov

Efficacy and Safety of Canakinumab in Schnitzler Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

December 31, 2011

Conditions
Schnitzler Syndrome
Interventions
DRUG

Canakinumab

Monthly subcutaneous injection with 150mg Canakinumab for 6 months

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Centre, Nijmegen

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Radboud University Medical Center

OTHER